Brief: Enlivex Announces Issuance Of New U.S. Patent Covering Methods Of Treating Gout, Inflammatory Bowel Disease, Crohn’S Disease, Ulcerative Colitis And GvHD Using Allocetra Immunotherapy
16/02/2021 13:52
Feb 16 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES ISSUANCE OF NEW U.S. PATENT COVERING
METHODS
OF TREATING GOUT, INFLAMMATORY BOWEL DISEASE, CROHN’S DISEASE,
ULCERATIVE COLITIS AND GVHD USING ALLOCETRA IMMUNOTHERAPY
Source text for Eikon: ID:nGNX9r6lfJ
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment